¼¼°èÀÇ ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀå
Zika Virus Testing
»óǰÄÚµå : 1761142
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 158 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,068,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,204,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3¾ï 1,450¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 2,450¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 5.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3¾ï 1,450¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÐÀÚ °Ë»ç´Â CAGR 6.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 9,240¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç÷ûÇÐÀû °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5,870¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀåÀº 2024³â¿¡ 5,870¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 9.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 7,550¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.2%¿Í 5.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÁöÄ«¹ÙÀÌ·¯½ºÀÇ È®»êÀº È¿°úÀûÀÎ °Ë»ç ¼Ö·ç¼ÇÀÇ Çʿ伺À» ¾î¶»°Ô ÃËÁøÇϰí Àִ°¡?

¸ð±â ¸Å°³ °¨¿°º´ÀÎ ÁöÄ«¹ÙÀÌ·¯½ºÀÇ À¯ÇàÀº ƯÈ÷ ¿­´ë ¹× ¾Æ¿­´ë Áö¿ª¿¡¼­ ½É°¢ÇÑ °øÁߺ¸°Ç ¹®Á¦·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ¼ÒµÎÁõ°ú °°Àº ½É°¢ÇÑ ¼±Ãµ¼º ±âÇü ¹× ±âŸ ½Å°æÇÐÀû ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â ÁöÄ«¹ÙÀÌ·¯½º °¨¿°ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ °Ë»ç ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«, Ä«¸®ºêÇØ, µ¿³²¾Æ½Ã¾Æ, ¾ÆÇÁ¸®Ä« ÀϺΠ±¹°¡¿¡¼­´Â ´Ù¼öÀÇ °¨¿° »ç·Ê°¡ º¸°íµÇ°í ÀÖÀ¸¸ç, Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ±ä±ÞÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è º¸°Ç ´ç±¹°ú Á¶Á÷Àº ¹ÙÀÌ·¯½º È®»êÀ» ¹æÁöÇϰí ÀáÀçÀûÀÎ ¹ßº´À» °ü¸®Çϱâ À§ÇØ Á¶±â Áø´Ü¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç´Â Áúº´ °¨½Ã ÇÁ·Î±×·¥ÀÇ Áß¿äÇÑ ¿ä¼Ò°¡ µÇ¾î ºÐÀÚ ºÐ¼®, Ç÷ûÇÐÀû °Ë»ç, ÇöÀå Áø´Ü µî ´Ù¾çÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú Çõ½ÅÀÌ ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ´É·ÂÀ» Çâ»ó½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ´É·ÂÀ» Å©°Ô Çâ»ó½ÃÄÑ º¸´Ù Á¤È®ÇÏ°í ½Å¼ÓÇÏ¸ç ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(RT-PCR) °Ë»ç¿Í °°Àº ºÐÀÚÁø´ÜÀÇ Çõ½ÅÀº ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ¸·Î ÀÎÇØ ÁöÄ«¹ÙÀÌ·¯½º °ËÃâÀÇ »õ·Î¿î Ç¥ÁØÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â °¨¿° ÈÄ ¸çÄ¥ À̳»¿¡ ¹ÙÀÌ·¯½º RNA¸¦ °ËÃâÇÒ ¼ö ÀÖ¾î Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, µ­±â¿­°ú Ä¡Äﱸ´Ï¾Æ¿Í °°Àº ¿©·¯ Çöóºñ ¹ÙÀÌ·¯½º¸¦ µ¿½Ã¿¡ °Ë»çÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º ºÐ¼®¹ýÀÌ °³¹ßµÇ¾î ÀÇ·á ¼­ºñ½º Á¦°øÀÚµé »çÀÌ¿¡¼­ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å¼ÓÁø´Ü °Ë»ç(RDT) ¹× ÈÞ´ë¿ë ÇÙ»ê ÁõÆø°Ë»ç(NAAT)¿Í °°Àº POCT(Point-of-care testing) ¼Ö·ç¼ÇÀº »ç¿ëÀÌ °£ÆíÇϰí, °¡°ÝÀÌ Àú·ÅÇϸç, ¹ßº´ ´ëÀÀ¿¡ ÇʼöÀûÀÎ ½Å¼ÓÇÑ °Ë»ç °á°ú¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÀÚ±Ý Á¶´Þ ÀÌ´Ï¼ÅÆ¼ºê°¡ ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀå Çü¼º¿¡´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÀÚ±Ý Á¶´Þ ÀÌ´Ï¼ÅÆ¼ºê°¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú ¼¼°èº¸°Ç±â±¸(WHO)¿Í °°Àº Á¤ºÎ ±â°üÀº ÁöÄ«¹ÙÀÌ·¯½º¿¡ ´ëÇÑ »õ·Î¿î Áø´Ü °Ë»çÀÇ ½ÂÀÎ ¹× °ËÁõ¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖÀ¸¸ç, ÇÊ¿äÇÑ ¹Î°¨µµ¿Í ƯÀ̵µ ±âÁØÀ» ÃæÁ·ÇÏ´ÂÁö È®ÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ä±Þ»ç¿ë½ÂÀÎ(EUA)ÀÌ °¡´ÉÇØÁü¿¡ µû¶ó Çõ½ÅÀûÀÎ Áø´Ü µµ±¸ÀÇ ½ÃÀå ÁøÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÚ±Ý Ãø¸é¿¡¼­´Â Á¤ºÎ±â°ü, ºñÁ¤ºÎ±â±¸(NGO), ¹Î°£´ÜüÀÇ ÅõÀÚ Áõ°¡°¡ ÷´Ü ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ±â¼úÀÇ °³¹ß°ú »ó¿ëÈ­¿¡ Å« µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦Àû Àμ¾Æ¼ºê´Â R&D Ȱµ¿À» ÃËÁøÇϰí, Àü ¼¼°è º¸°Ç ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ º¸´Ù °­·ÂÇϰí È®Àå °¡´ÉÇÑ °Ë»ç ¼Ö·ç¼ÇÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù.

ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ÁöÄ«¹ÙÀÌ·¯½º °¨¿° Áõ°¡, ºÐÀÚÁø´Ü ±â¼ú ¹× ÇöÀå Áø´Ü ±â¼úÀÇ ¹ßÀü, ÇコÄɾî ÀÎÇÁ¶ó ¹× Áúº´ °¨½Ã ÅõÀÚ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÁöÄ«¹ÙÀÌ·¯½º¿Í ´Ù¸¥ Çöóºñ ¹ÙÀÌ·¯½º°¡ °øÁ¸ÇÏ´Â À¯Çà Áö¿ª¿¡¼­´Â Áý´Ü ¹ßº´ ½Ã ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺ÀÌ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º ºÐ¼® ¹× ÈÞ´ë¿ë NAAT¿Í °°Àº ±â¼ú ¹ßÀüÀº °Ë»ç ´É·ÂÀ» Çâ»ó½Ã۰í, ¿ø°ÝÁö ¹× ÀÚ¿øÀÌ Á¦ÇÑµÈ Áö¿ªÀ¸·ÎÀÇ ½ÃÀå ÁøÀÔÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú Á¤ºÎÀÇ ÀçÁ¤ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê´Â ÁöÄ«¹ÙÀÌ·¯½º °Ë»çÀÇ °¡¿ë¼º°ú Á¢±Ù¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü°ú ¿¹¹æÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ·áÁø°ú ÀÏ¹Ý ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÁöÄ«¹ÙÀÌ·¯½º °Ë»ç´Â Àü ¼¼°è º¸°Ç ¾Èº¸ÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(ºÐÀÚ °Ë»ç, Ç÷û °Ë»ç), ÃÖÁ¾»ç¿ëÀÚ(Á¶»ç±â°ü, Áø´Ü ¿¬±¸¼Ò, º´¿ø¡¤Áø·á¼Ò)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 11°³»ç)

AI ÅëÇÕ

´ç»ç´Â, °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Zika Virus Testing Market to Reach US$314.5 Million by 2030

The global market for Zika Virus Testing estimated at US$224.5 Million in the year 2024, is expected to reach US$314.5 Million by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Molecular Testing, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$192.4 Million by the end of the analysis period. Growth in the Serological Testing segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$58.7 Million While China is Forecast to Grow at 9.9% CAGR

The Zika Virus Testing market in the U.S. is estimated at US$58.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$75.5 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Zika Virus Testing Market - Key Trends & Drivers Summarized

How Is the Rising Prevalence of Zika Virus Driving the Need for Effective Testing Solutions?

The outbreak of the Zika virus, a mosquito-borne disease, has emerged as a significant public health challenge, particularly in tropical and subtropical regions. The increasing prevalence of Zika virus infections, which can lead to severe birth defects such as microcephaly and other neurological complications, has underscored the need for effective testing solutions. Countries in Latin America, the Caribbean, Southeast Asia, and parts of Africa have reported numerous cases, driving urgent demand for accurate and rapid diagnostic tests. Healthcare authorities and organizations worldwide are emphasizing early diagnosis to prevent the spread of the virus and manage potential outbreaks. Consequently, Zika virus testing has become a critical component of disease surveillance programs, boosting the demand for a variety of diagnostic tests, including molecular assays, serological tests, and point-of-care diagnostics.

What Technological Innovations Are Enhancing Zika Virus Testing Capabilities?

Technological advancements are significantly enhancing the capabilities of Zika virus testing, enabling more accurate, rapid, and reliable diagnosis. Innovations in molecular diagnostics, such as real-time polymerase chain reaction (RT-PCR) tests, have set a new standard for Zika detection due to their high sensitivity and specificity. These tests can detect the viral RNA within days of infection, providing crucial information for timely intervention. Additionally, the development of multiplex assays that can simultaneously test for multiple flaviviruses, such as dengue and chikungunya, is gaining traction among healthcare providers. Point-of-care testing (POCT) solutions, such as rapid diagnostic tests (RDTs) and portable nucleic acid amplification tests (NAATs), are also becoming popular in resource-limited settings due to their ease of use, affordability, and ability to deliver quick results, which are essential for outbreak control.

How Are Regulatory Approvals and Funding Initiatives Influencing the Zika Virus Testing Market?

Regulatory approvals and funding initiatives play a crucial role in shaping the Zika virus testing market. Government agencies, such as the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO), have been actively involved in approving and validating new diagnostic tests for Zika virus, ensuring they meet the necessary sensitivity and specificity criteria. Additionally, the availability of emergency use authorizations (EUAs) has accelerated the market entry of innovative diagnostic tools during outbreaks. On the funding side, increased investment from government bodies, non-governmental organizations (NGOs), and private entities has significantly supported the development and commercialization of advanced Zika virus testing technologies. These financial incentives are driving research and development activities, promoting the availability of more robust and scalable testing solutions to address global health concerns.

The Growth in the Zika Virus Testing Market Is Driven by Several Factors

The growth in the Zika virus testing market is driven by several factors, including the increasing prevalence of Zika infections, advancements in molecular and point-of-care diagnostic technologies, and rising investments in healthcare infrastructure and disease surveillance. The need for rapid and accurate diagnosis during outbreaks is a significant driver, particularly in endemic regions where Zika co-circulates with other flaviviruses. Technological advancements, such as multiplex assays and portable NAATs, are enhancing testing capabilities and expanding the market's reach to remote and resource-limited areas. Additionally, regulatory approvals and government funding initiatives are boosting the availability and accessibility of Zika virus tests. The growing awareness among healthcare providers and the general public about the importance of early diagnosis and prevention is also contributing to market growth, making Zika virus testing a vital component of global health security.

SCOPE OF STUDY:

The report analyzes the Zika Virus Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Molecular Testing, Serological Testing); End-Use (Research Institutes, Diagnostic Laboratories, Hospitals & Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â